A detailed history of Aqr Capital Management LLC transactions in Enanta Pharmaceuticals Inc stock. As of the latest transaction made, Aqr Capital Management LLC holds 37,859 shares of ENTA stock, worth $353,603. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,859
Previous 60,005 36.91%
Holding current value
$353,603
Previous $778,000 49.61%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$10.05 - $16.54 $222,567 - $366,294
-22,146 Reduced 36.91%
37,859 $392,000
Q2 2024

Aug 14, 2024

SELL
$11.43 - $17.02 $568,082 - $845,911
-49,701 Reduced 45.3%
60,005 $778,000
Q1 2024

May 15, 2024

SELL
$10.08 - $17.46 $943,064 - $1.63 Million
-93,558 Reduced 46.03%
109,706 $1.92 Million
Q4 2023

Feb 14, 2024

BUY
$8.18 - $10.78 $535,691 - $705,960
65,488 Added 47.53%
203,264 $1.91 Million
Q3 2023

Nov 14, 2023

BUY
$11.09 - $22.13 $1.31 Million - $2.62 Million
118,320 Added 608.14%
137,776 $1.54 Million
Q2 2023

Aug 14, 2023

BUY
$20.68 - $39.85 $196,253 - $378,176
9,490 Added 95.22%
19,456 $416,000
Q1 2023

May 15, 2023

SELL
$38.82 - $54.59 $281,872 - $396,377
-7,261 Reduced 42.15%
9,966 $403,000
Q4 2022

Feb 14, 2023

BUY
$40.77 - $53.73 $306,101 - $403,404
7,508 Added 77.25%
17,227 $801,000
Q3 2022

Nov 14, 2022

BUY
$48.29 - $71.27 $107,638 - $158,860
2,229 Added 29.76%
9,719 $504,000
Q2 2022

Aug 15, 2022

SELL
$38.13 - $76.93 $19,179 - $38,695
-503 Reduced 6.29%
7,490 $354,000
Q1 2022

May 16, 2022

SELL
$56.06 - $74.11 $343,087 - $453,553
-6,120 Reduced 43.36%
7,993 $569,000
Q4 2021

Feb 14, 2022

BUY
$60.19 - $97.37 $454,675 - $735,532
7,554 Added 115.17%
14,113 $1.06 Million
Q3 2021

Nov 15, 2021

SELL
$41.02 - $58.65 $57,715 - $82,520
-1,407 Reduced 17.66%
6,559 $373,000
Q2 2021

Aug 16, 2021

SELL
$43.76 - $53.11 $9,102 - $11,046
-208 Reduced 2.54%
7,966 $351,000
Q1 2021

May 17, 2021

SELL
$41.69 - $54.95 $1.15 Million - $1.52 Million
-27,623 Reduced 77.17%
8,174 $403,000
Q4 2020

Feb 16, 2021

SELL
$41.16 - $47.47 $345,744 - $398,748
-8,400 Reduced 19.01%
35,797 $1.51 Million
Q3 2020

Nov 16, 2020

SELL
$43.36 - $53.53 $781,737 - $965,092
-18,029 Reduced 28.97%
44,197 $2.02 Million
Q2 2020

Aug 17, 2020

SELL
$46.37 - $57.58 $729,353 - $905,675
-15,729 Reduced 20.18%
62,226 $3.12 Million
Q1 2020

May 15, 2020

SELL
$40.22 - $62.0 $1.5 Million - $2.31 Million
-37,276 Reduced 32.35%
77,955 $4.01 Million
Q4 2019

Feb 14, 2020

SELL
$57.95 - $66.61 $1.31 Million - $1.51 Million
-22,604 Reduced 16.4%
115,231 $7.12 Million
Q3 2019

Nov 14, 2019

BUY
$60.08 - $88.17 $825,018 - $1.21 Million
13,732 Added 11.07%
137,835 $8.28 Million
Q2 2019

Aug 14, 2019

SELL
$81.3 - $97.35 $1.5 Million - $1.8 Million
-18,461 Reduced 12.95%
124,103 $10.5 Million
Q1 2019

May 14, 2019

SELL
$69.08 - $105.66 $3.12 Million - $4.78 Million
-45,235 Reduced 24.09%
142,564 $13.6 Million
Q4 2018

Feb 14, 2019

BUY
$65.41 - $84.65 $3.82 Million - $4.95 Million
58,463 Added 45.2%
187,799 $13.3 Million
Q3 2018

Nov 15, 2018

BUY
$85.46 - $126.37 $763,670 - $1.13 Million
8,936 Added 7.42%
129,336 $11.1 Million
Q2 2018

Aug 14, 2018

SELL
$81.85 - $120.51 $1.06 Million - $1.57 Million
-13,009 Reduced 9.75%
120,400 $14 Million
Q1 2018

May 15, 2018

SELL
$57.91 - $92.15 $1.26 Million - $2.01 Million
-21,773 Reduced 14.03%
133,409 $10.8 Million
Q4 2017

Feb 14, 2018

SELL
$45.65 - $59.37 $128,322 - $166,889
-2,811 Reduced 1.78%
155,182 $9.11 Million
Q3 2017

Nov 14, 2017

BUY
$37.91 - $46.8 $5.99 Million - $7.39 Million
157,993
157,993 $7.39 Million

Others Institutions Holding ENTA

About ENANTA PHARMACEUTICALS INC


  • Ticker ENTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,724,900
  • Market Cap $194M
  • Description
  • Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...
More about ENTA
Track This Portfolio

Track Aqr Capital Management LLC Portfolio

Follow Aqr Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aqr Capital Management LLC with notifications on news.